Traws Pharma, Inc. — Director's Dealing 2025

Jan 28, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Traws Pharma, Inc. (TRAW)
CIK: 0001130598
Period of Report: 2024-12-29

Reporting Person: CAUTREELS WERNER (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-29	Pre-Funded Warrant (right to buy)	$0.01	P	96348	Acquired		Common Stock (96348)	Direct
2024-12-29	Series A Warrant (right to buy)	$13.42	P	96348	Acquired		Common Stock (96348)	Direct

Footnotes

F1: The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules.

F2: The Pre-Funded Warrants do not expire.

F3: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit.

F4: The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules.

F5: The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data.